FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial. PMID 35834226 · JAMA Oncol · 2022-Sep-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Comparing Effect of Adding Ketamine Versus Dexmedetomidine to Bupivacaine in Pecs-ⅠⅠ Block on Postoperative Pain Control in Patients Undergoing Breast Surgery. PMID 35777735 · Clin J Pain · 2022-Sep-01 The record describes a randomized, double-blind trial evaluating pain control interventions (anesthetics/adjuvants) for breast cancer surgery. It meets oncology, human, randomized, original result, and drug intervention criteria. However, it is excluded because: 1) The primary endpoint is total morphine consumption (continuous), not a time-to-event efficacy endpoint (OS/PFS/etc.); 2) No phase is specified, and the trial is not a definitive Phase III/IIIb or Phase II/III cancer treatment trial; 3) No Kaplan-Meier or HR analysis is reported for any survival or progression endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Trial. PMID 35763041 · Clin Cancer Res · 2022-Sep-01 While the underlying trial is randomized and oncology-focused with drug intervention and a time-to-event component, this specific record is an exploratory biomarker analysis (secondary report) from the trial, not the primary or definitive trial efficacy report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-term Outcomes of Parenchyma-sparing and Oncologic Resections in Patients With Nonfunctional Pancreatic Neuroendocrine Tumors <3 cm in a Large Multicenter Cohort. PMID 35758433 · Ann Surg · 2022-Sep-01 Study is a retrospective cohort comparison of surgical procedures, not a randomized drug trial. It lacks both randomization and a drug intervention, which are required for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Reversing the Genomic, Epigenetic, and Triple-Negative Breast Cancer-Enhancing Effects of Obesity. PMID 35696725 · Cancer Prev Res (Phila) · 2022-Sep-01 The record describes a preclinical animal study in mice, not a human clinical trial. It does not meet the core eligibility criteria for human randomized Phase III/IIIb or Phase II/III trials with drug intervention and time-to-event efficacy endpoints. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| FOXM1 Variant Contributes to Gefitinib Resistance via Activating Wnt/β-Catenin Signal Pathway in Patients with Non-Small Cell Lung Cancer. PMID 35695863 · Clin Cancer Res · 2022-Sep-01 The record describes a translational study analyzing genetic polymorphisms in patients receiving gefitinib, with randomized allocation for exploratory and validation analysis, but it does not represent a Phase II/III or Phase III randomized controlled trial comparing drug interventions. Therefore, it does not meet the core eligibility criteria for a definitive-phase trial report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response. PMID 35511938 · Clin Cancer Res · 2022-Sep-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Dose- and Volume-Limiting Late Toxicity of FLASH Radiotherapy in Cats with Squamous Cell Carcinoma of the Nasal Planum and in Mini Pigs. PMID 35421221 · Clin Cancer Res · 2022-Sep-01 The study is a randomized phase III trial with primary results, but it is not eligible because it is an animal study (cats), the intervention is not drug-containing, and the endpoints are not time-to-event efficacy outcomes. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. PMID 35377708 · J Clin Oncol · 2022-Sep-01 The record is an original, secondary analysis of a Phase III trial focusing on the prognostic value of MRD. It is not the primary efficacy report of the randomized drug intervention (lenalidomide maintenance) itself. The intervention is a background factor in the analysis of MRD, not the main subject of evaluation. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Follicular lymphoma grade 3B and diffuse large B-cell lymphoma present a histopathological and molecular continuum lacking features of progression/ transformation. PMID 35021600 · Haematologica · 2022-Sep-01 The record describes results from a prospective randomized trial in lymphoma patients with time-to-event endpoints and a drug intervention, but the provided metadata (title, abstract, and publication tags) does not explicitly establish the trial phase as Phase III/IIIb or Phase II/III, which is a required criterion for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. PMID 38319800 · NEJM Evid · 2022-Sep The record explicitly meets all required eligibility criteria for inclusion in the cohort. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| A cluster randomized controlled trial to evaluate the efficacy of esophageal and gastric cancer screening in mortality reduction in a non-high-incidence area: methodology and initial results. PMID 36267765 · Ann Transl Med · 2022-Sep This is a randomized trial of cancer screening (endoscopy-based) vs. control, not a therapeutic drug trial. It lacks a drug-containing intervention and the primary endpoint is mortality reduction (rate), not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) with Kaplan-Meier or HR analysis. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparison of analgesic effect in celiac plexus neurolysis: Ethanol injection with or without iodine-125 radioactive seeds implantation. PMID 36204877 · J Cancer Res Ther · 2022-Sep The study is a randomized trial in oncology patients but is not eligible: phase is not specified and likely early (pilot with n=10); the primary endpoint is pain score (NRS), not a time-to-event efficacy endpoint; and the intervention is a palliative procedure, not a systemic drug therapy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Multicenter, Randomized, Double-Blinded, Clinical Trial Comparing Cattell-Warren and Blumgart Anastomoses Following Partial Pancreatoduodenectomy: PANasta Trial. PMID 36199490 · Ann Surg Open · 2022-Sep The trial is a randomized comparison of two surgical techniques for anastomosis after pancreatic cancer surgery. While it is an oncology-related human trial with a time-to-event endpoint (survival) as a secondary outcome, it lacks a drug-containing intervention, which is a required criterion. The trial phase is not specified in the metadata. Therefore, it does not meet the eligibility criteria for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cost Study of the PlasmaJet Surgical Device Versus Conventional Cytoreductive Surgery in Patients With Advanced-Stage Ovarian Cancer. PMID 36198130 · JCO Clin Cancer Inform · 2022-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| The Effects of Standardised versus Individualised Aerobic Exercise Prescription on Fitness-Fatness Index in Sedentary Adults: A Randomised Controlled Trial. PMID 36157386 · J Sports Sci Med · 2022-Sep The study is not oncology-focused, does not involve a drug intervention, and does not assess a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Integrated Geriatric Assessment and Treatment Effectiveness (INTEGERATE) in older people with cancer starting systemic anticancer treatment in Australia: a multicentre, open-label, randomised controlled trial. PMID 36102776 · Lancet Healthy Longev · 2022-Sep The trial is eligible for oncology and randomization criteria, but it is excluded because the primary endpoint is quality of life, not a time-to-event efficacy endpoint. The study phase is also not explicitly confirmed as Phase III or equivalent. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Radiomics signature for predicting postoperative disease-free survival of patients with gastric cancer: development and validation of a predictive nomogram. PMID 36097638 · Diagn Interv Radiol · 2022-Sep The study is a retrospective analysis of a predictive nomogram for disease-free survival in gastric cancer patients after surgery. It is not a Phase III/IIIb or Phase II/III randomized trial of a drug intervention. While it is randomized for training/validation split, it is not a clinical trial comparing drug interventions. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis. PMID 36096534 · J Immunother Cancer · 2022-Sep The record is an original result report of a drug intervention in oncology, but it fails key eligibility criteria: it is not randomized, not a Phase III/IIIb trial, and lacks a time-to-event primary/key secondary efficacy endpoint. The study is a single-arm investigation of tocilizumab for managing checkpoint inhibitor side effects, not a definitive randomized trial of antitumor efficacy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey. PMID 36040321 · Future Oncol · 2022-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Characteristics of adverse event reporting of Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to the US Food and Drug Administration. PMID 36001100 · J Manag Care Spec Pharm · 2022-Sep This is a safety analysis of adverse event reports from the FDA database, not a report of a randomized trial's efficacy results with a time-to-event endpoint. The publication type includes 'Randomized Controlled Trial', but the abstract describes a study of reported adverse events, not the primary or key secondary efficacy analysis of a trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314). PMID 35970102 · Eur J Cancer · 2022-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial. PMID 35922444 · Leukemia · 2022-Sep The study is a randomized, human, oncology trial with a drug intervention, but the abstract does not explicitly report a primary or key secondary time-to-event efficacy endpoint. It describes a genomic and prognostic analysis within the trial, not the trial's primary efficacy results for survival outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study. PMID 35902297 · Gynecol Oncol · 2022-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A review of patient-reported outcome assessments in registration trials of FDA-approved new oncology drugs (2014-2018). PMID 35901962 · Contemp Clin Trials · 2022-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial. PMID 35872530 · Lung Cancer · 2022-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase III PEGASUS study. PMID 35869984 · Ann Hematol · 2022-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome. PMID 35869267 · Leukemia · 2022-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The Comparison of Postoperative Analgesic Efficacy of Ultrasound-Guided Paravertebral Block and Mid-Point Transverse Process Pleura Block in Mastectomy Surgeries: A Randomized Study. PMID 35848451 · J Invest Surg · 2022-Sep 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| HYPORT adjuvant acute toxicity and patient dosimetry quality assurance results - Interim analysis. PMID 35817323 · Radiother Oncol · 2022-Sep 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
B
|
旧查询独有 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy. PMID 35790566 · Cardiovasc Intervent Radiol · 2022-Sep The record describes a single-arm, prospective Phase II/III feasibility and training study (DRAGON 1) for a device-based embolization procedure (PVE/HVE), with no drug intervention and no reported results. It does not meet the criteria for a Phase III/IIIb or Phase II/III randomized drug trial with time-to-event efficacy results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A novel prognostic model predicting overall survival in patients with metastatic castration-resistant prostate cancer receiving standard chemotherapy: A multi-trial cohort analysis. PMID 35790016 · Prostate · 2022-Sep This record is a prognostic model development study using pooled data from control arms of multiple prior RCTs. It is not an original report of a single Phase III/IIIb or Phase II/III randomized trial's efficacy results. The phase of the underlying trials is not explicitly stated in the provided metadata, and the analysis is secondary in nature, focusing on model building rather than trial outcomes. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of recombinant human endostatin combined with whole-brain radiation therapy in patients with brain metastases from non-small cell lung cancer. PMID 35788355 · Radiother Oncol · 2022-Sep The study meets most criteria (oncology, human, randomized, drug intervention, original result with KM endpoints) but does not explicitly establish a Phase III/IIIb or Phase II/III trial. The small sample size (n=43) and the lack of a clear phase designation in the metadata or abstract suggest it is likely a Phase II trial, which is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Re: Chemoradiotherapy in Muscle-invasive Bladder Cancer (BC2001): 10-year Follow-up of a Phase 3 Randomised Controlled Trial. PMID 35787935 · Eur Urol · 2022-Sep 虽然满足肿瘤学、人类、随机化、III期和原始结果标准,但未检测到明确的time-to-event终点(如OS、PFS等)或Kaplan-Meier/HR证据。此外,虽然标题暗示'Chemoradiotherapy',但未明确检测到药物干预信号,可能为放疗方案而非药物特异性试验。 |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Diagnostic value of whole-tumor apparent diffusion coefficient map radiomics analysis in predicting early recurrence of solitary hepatocellular carcinoma ≤ 5 cm. PMID 35776146 · Abdom Radiol (NY) · 2022-Sep Study is a retrospective diagnostic prediction analysis for early recurrence in hepatocellular carcinoma using radiomics. It lacks explicit phase III/IIIb trial status, does not involve a drug intervention, and uses ROC/AUC analysis rather than time-to-event survival endpoints (OS, PFS, DFS, KM curves, HR). |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| [High risk localized and locally advanced prostate cancer: Long-term oncological outcomes after prostatectomy]. PMID 35773175 · Prog Urol · 2022-Sep The record is a retrospective cohort study, not a randomized trial, and lacks a drug-containing intervention, which are required for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide. PMID 35764236 · J Thorac Oncol · 2022-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery in patients with locally advanced esophageal squamous cell carcinoma who achieved clinical complete response when induction chemoradiation finished: A phase II random. PMID 35764191 · Radiother Oncol · 2022-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Clinical trial data of Anti-PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: A review. PMID 35753157 · Cancer Treat Rev · 2022-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| CT-based radiomics nomogram may predict local recurrence-free survival in esophageal cancer patients receiving definitive chemoradiation or radiotherapy: A multicenter study. PMID 35750106 · Radiother Oncol · 2022-Sep The record describes a retrospective, multicenter study developing and validating a radiomics nomogram for predicting local recurrence-free survival in esophageal cancer patients treated with standard-of-care chemoradiation/radiotherapy. While it is oncology, human, includes a time-to-event endpoint, and is a primary result, it fails the core eligibility criteria: it is not a randomized trial of a drug intervention (it is a predictive model study), and there is no evidence it is a Phase III/IIIb or Phase II/III therapeutic trial. The randomization mentioned is for splitting data into training/validation sets, not for comparing therapeutic arms. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Certolizumab Pegol Efficacy in Patients With Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status: An Analysis From the C-axSpAnd Study. PMID 35733363 · ACR Open Rheumatol · 2022-Sep The study is a Phase 3 randomized trial of certolizumab pegol in non-radiographic axial spondyloarthritis. While it meets criteria for being a human, randomized, drug-intervention Phase 3 trial, it is excluded because it is not an oncology study (it investigates a rheumatologic disease), the primary efficacy endpoints are not time-to-event outcomes, and the report is a subgroup analysis. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A novel digital rectoscope for the triage of lower gastrointestinal symptoms in primary care: a prospective multicentre feasibility study. PMID 35728817 · BJGP Open · 2022-Sep This is a Phase I feasibility study of a device (digital rectoscope), not a randomized Phase III/IIIb or Phase II/III drug trial. It does not report a primary or key secondary time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of vitamin C on immune reconstitution after bone marrow transplantation. PMID 35713160 · Int J Clin Pharmacol Ther · 2022-Sep The study is a randomized trial in an oncology population (post-HSCT for myeloma/lymphoma) but does not meet key eligibility criteria: it lacks a drug-containing intervention (vitamin C is a supplement), it is not explicitly a Phase III/IIIb or Phase II/III trial, and most critically, it does not report a time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier or HR data. The primary outcome is immune reconstitution and infection frequency. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Germline Polymorphisms in Genes Involved in the Antioxidant System Predict the Efficacy of Cetuximab in Metastatic Colorectal Cancer Patients Enrolled in FIRE-3 Trial. PMID 35710481 · Clin Colorectal Cancer · 2022-Sep This is a secondary biomarker analysis from a Phase III randomized trial (FIRE-3). The primary endpoint of the original trial (PFS, OS) is not the focus of this report; the report is a pre-planned analysis of a predictive biomarker (SNP) for treatment efficacy. It is not the primary or key secondary result report of the trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Role of the pre- to postoperative alpha-fetoprotein ratio in the prognostic evaluation of liver cancer after radiofrequency ablation. PMID 35686334 · Int J Biol Markers · 2022-Sep The study is a retrospective prognostic analysis of an imaging/procedural intervention (RFA) and a biomarker (AFP ratio) in hepatocellular carcinoma. It does not meet the criteria for a Phase III/IIIb or Phase II/III randomized trial of a drug-containing intervention with a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A pilot study on preoperative vascular anatomy and clinical application in rectal cancer resection. PMID 35680447 · Clin Radiol · 2022-Sep 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Randomized trial of sucrosomial iron supplementation in patients with chemotherapy-related anemia treated with ESA. PMID 35678882 · Support Care Cancer · 2022-Sep The primary endpoint is the proportion of patients achieving complete hematological response at 12 weeks, which is a binary outcome, not a time-to-event endpoint as defined by the cohort criteria (e.g., OS, PFS, DFS, Kaplan-Meier analysis, HR). Therefore, it does not meet the required time-to-event efficacy endpoint criterion. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Induction Chemotherapy and Chemoradiotherapy Combined to ASA vs. Placebo for High-Risk Rectal Cancer: Results of a Randomized Trial. PMID 35668002 · Clin Colorectal Cancer · 2022-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Self-Efficacy for Symptom Management in Long-Term Adult Hematopoietic Stem Cell Survivors. PMID 35662590 · Transplant Cell Ther · 2022-Sep The record does not meet key eligibility criteria: it is not a drug intervention trial, it does not have a time-to-event efficacy endpoint, and it is not a report of the primary trial results for such an endpoint. The study is a cross-sectional analysis of baseline data from a randomized psychosocial intervention trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Sugammadex Versus Neostigmine for Neuromuscular Block Reversal and Postoperative Pulmonary Complications in Patients Undergoing Resection of Lung Cancer. PMID 35662514 · J Cardiothorac Vasc Anesth · 2022-Sep While the study is an oncology-related randomized trial with a drug intervention, it does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier). The endpoints focus on postoperative complications and recovery metrics, not cancer efficacy outcomes. Therefore, it does not meet the required criteria for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |